Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model

JAMA Oncol. 2016 Sep 1;2(9):1125-6. doi: 10.1001/jamaoncol.2016.2037.

Authors

Thomas J Hwang¹, John L LaMattina²

Affiliations

¹ Faculty of Arts and Sciences, Harvard University, Boston, Massachusetts2Brigham and Women's Hospital, Boston, Massachusetts.
² PureTech, Boston, Massachusetts.

PMID: 27388928
DOI: 10.1001/jamaoncol.2016.2037

No abstract available

MeSH terms

Antineoplastic Agents / economics*
Drug Costs
Health Expenditures*
Health Policy / economics*
Humans
Medicare Part B / economics*
Neoplasms / drug therapy*
Pharmaceutical Preparations / economics
Reimbursement Mechanisms
United States
Value-Based Purchasing*

Substances

Antineoplastic Agents
Pharmaceutical Preparations